Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 18, 2008, Pages 5010-5014

  Ogino, Yoshio ^a   Ohtake, Norikazu ^a   Nagae, Yoshikazu ^a   Matsuda, Kenji ^a   Moriya, Minoru ^a   Suga, Takuya ^a   Ishikawa, Makoto ^a   Kanesaka, Maki ^a   Mitobe, Yuko ^a   Ito, Junko ^a   Kanno, Tetsuya ^a   Ishihara, Akane ^a   Iwaasa, Hisashi ^a   Ohe, Tomoyuki ^a   Kanatani, Akio ^a   Fukami, Takehiro ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antagonist; Anti obesity; Benzimidazole; Neuropeptide Y; Y5 receptor

Indexed keywords

2 [3 OXOSPIRO(ISOBENZOFURAN 1(3H),4' PIPERIDIN) 1' YL]BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y5 RECEPTOR; UNCLASSIFIED DRUG; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FOOD INTAKE; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BENZIMIDAZOLES; BRAIN; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; MOLECULAR STRUCTURE; RATS; RECEPTORS, NEUROPEPTIDE Y; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 51349162920     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.08.018     Document Type: Article

References (35)

1. Tatemoto K., and Mutt M. Nature 285 (1980) 417
2. Tatemoto K., Carlquist M., and Mutt V. Nature 296 (1982) 659
3. Stanley B.G., Kyrkouli S.E., Lampert S., and Leibowitz S.F. Peptides 7 (1986) 1189
4. Zarjevski N., Cusin I., Vettor R., Rohner-Jeanrenaud F., and Jeanrenaud B. Endocrinology 133 (1993) 1753
5. Clark J.T., Kalra P.S., Crowley W.R., and Kalra S.P. Endocrinology 115 (1984) 427
6. Stanley B.G., Magdalin W., Seirafi A., Nguyen M.M., and Leibowitz S.F. Peptides 13 (1992) 1189
7. Parrott R.F., Heavens R.P., and Baldwin B.A. Physiol. Behav. 36 (1986) 523
8. Sakatani N., Inui A., Inoue T., Oya M., Morioka H., and Baba S. Peptides 8 (1987) 651
9. Miner J.L., Della-Fera M.A., Paterson J.A., and Baile C.A. Am . J . Physiol. 257 (1989) R383
10. Blomqvist A.G., and Herzog H. Trends Neurosci. 20 (1997) 294
11. Gerald C., Walker M.W., Criscione L., Gustafson E.L., Batzl-Hartmann C., Smith K.E., Vaysse P., Durkin M.M., Laz T.M., Linemeyer D.L., Schaffhauser A.O., Whitebread S., Hofbauer K.G., Taber R.I., Branchek T.A., and Weinshank R.L. Nature 382 (1996) 168
12. Kanatani A., Ishihara A., Iwaasa H., Nakamura K., Okamoto O., Hidaka M., Ito J., Fukuroda T., MacNeil D.J., Van der Ploeg L.H.T., Ishii Y., Okabe T., Fukami T., and Ihara M. Biochem. Biophys. Res. Commun. 272 (2000) 169
13. Ishihara A., Kanatani A., Mashiko S., Tanaka T., Hidaka M., Gomori A., Iwaasa H., Murai N., Egashira S., Murai T., Mitobe Y., Matsushita H., Okamoto O., Sato N., Jitsuoka M., Fukuroda T., Ohe T., Guan X., MacNeil D.J., Van der Ploeg L.H.T., Nishikibe M., Ishii Y., Ihara M., and Fukami T. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 7154
14. Erondu N., Gantz I., Musser B., Suryawanshi S., Mallick M., Addy C., Cote J., Bray G., Fujioka K., Bays H., Hollander P., Sanabria-Bohórquez S.M., Eng W., Långström B., Hargreaves R.J., Burns H.D., Kanatani A., Fukami T., MacNeil D.J., Gottesdiener K.M., Amatruda J.M., Kaufman K.D., and Heymsfield S.B. Cell Metabolism 4 (2006) 275
15. Rueeger H., Rigollier P., Yamaguchi Y., Schmidlin T., Shilling W.M., Criscione L., Whitebread S., Chiesi M., Walker M.W., Dhanoa D., Islam I., Zhang J., and Gluchowski C. Bioorg. Med. Chem. Lett. 10 (2000) 1175
16. Youngman M.A., McNally J.J., Lovenberg T.W., Reitz A.B., Willard N.M., Nepomuceno D.H., Wilson S.J., Crooke J.J., Rosenthal D., Vaidya A.H., and Dax S.L. J. Med. Chem. 43 (2000) 346
17. Norman M.H., Chen N., Chen Z., Fotsch C., Hale C., Han N., Hurt R., Jenkins T., Kincaid J., Liu L., Liu Y., Moreno O., Santora V.J., Sonnenberg J.D., and Karbon W. J. Med. Chem. 43 (2000) 4288
18. Itani H., Ito H., Sakata Y., Hatakeyama Y., Oohashi H., and Satoh Y. Bioorg. Med. Chem. Lett. 12 (2002) 799
19. Block M.H., Boyer S., Brailsford W., Brittain D.R., Carroll D., Chapman S., Clarke D.S., Donald C.S., Foote K.M., Godfrey L., Lander A., Marsham P.R., Masters D.J., Mee C.D., O'donovan M.R., Pease J.E., Pickup A.G., Rayner J.W., Roberts A., Schofield P., Suleman A., and Turnbull A.V. J. Med. Chem. 45 (2002) 3509
20. Sato N., Takahashi T., Shibata T., Haga Y., Sakuraba A., Hirose M., Sato M., Nonoshita K., Koike Y., Kitazawa H., Fujino N., Ishii Y., Ishihara A., Kanatani A., and Fukami T. J. Med. Chem. 46 (2003) 666
21. Elliot R.L., Oliver R.M., LaFlamme J.A., Gillaspy M.L., Hammond M., Hank R.F., Maurer T., Baker D.L., DaSilva-Jardine P.A., Stevenson R.W., Mack C.M., and Casella J.V. Bioorg. Med. Chem. Lett. 13 (2003) 3593
22. Guba W., Neidhart W., and Nettekoven M. Bioorg. Med. Chem. Lett. 15 (2005) 1599
23. Gillman K.W., Higgins M.A., Poindexter G.S., Browning M., Clarke W.J., Flowers S., Grace Jr. J.E., Hogan J.B., McGovern R.T., Iben L.G., Mattson G.L., Ortiz A., Rassnick S., Russell J.W., and Antal-Zimanyi I. Bioorg. Med. Chem. 14 (2006) 5517
24. Takahashi T., Sakuraba A., Hirohashi T., Shibata T., Hirose M., Haga Y., Nonoshita K., Kanno T., Ito J., Iwaasa H., Kanatani A., Fukami T., and Sato N. Bioorg. Med. Chem. 14 (2006) 7501
25. Gao, Y.; MacNeil, D. J.; Yang, L.; Morin, N. R.; Fukami, T.; Kanatani, A.; Fukuroda, T.; Ishii, Y.; Ihara, M. PCT Int. Appl. WO 2000027845.
26. Maligres P.E., Houpis I., Rosen K., Molina A., Sager J., Upadhyay V., Wells K.M., Reamer R.A., Lynch J.E., Askin D., Volante R.P., and Reider P.J. Tetrahedron 53 (1997) 10983
27. Fukami, T.; Kanatani, A.; Ishihara, A.; Ishii, Y.; Takahashi, T.; Haga, Y.; Sakamoto, T.; Itoh, T. PCT Int. Appl. WO 2001014376.
28. Marxer A., Rodriguez H.R., McKenna J.M., and Tsai H.M. J. Org. Chem. 40 (1975) 1427
29. Y5 receptor antagonists with benzimidazole structures were disclosed from Neurogen Co.; Bakthavatchalam, R.; Blum, C. A.; Brielmann, H. L.; Darrow, J. W.; Delombaert, S.; Hutchinson, A.; Tran, J.; Zheng, X.; Elliott, R. L.; Hammond, M. PCT Int. Appl. WO 2002048152.
30. Parrodi C.A., Quintero-Cortés L., and Sadoval-Ramírez J. Synth. Commun. 26 (1996) 3323
31. Generation of 8 was probably due to epimerization of the intermediate amide 21 under this acidic cyclization condition. The compound 8 was exclusively prepared from the cis-isomer of the carboxylic aid 20 (Ref. 10). The stereochemistry of the cis-carboxylic acid was unambiguously assigned by NOESY NMR experiment.
32. 50 of this compound is 1.8 ± 0.2 nM.
33. H, u int.: mL/min/kg) using rat hepatocytes (Shibata, Y.; Takahashi, H.; Ishii, Y. Drug Metab. Dispos. 2000, 28, 1518) were A, B for 5i and 5k, and B, C for 5r.
34. Parker E.M., Balasubramaniam A., Guzzi M., Mullins D.E., Salisbury B.G., Sheriff S., Wittten M.B., and Hwa J.J. Peptides 21 (2000) 393
35. 34 NPY.